The body's own repair peptide
Injection, Oral · 503A Compounding
Educational content. This page describes BPC-157 for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Researched and maintained by the PepHookup team. Regulatory status last verified April 12, 2026.
Modulates the nitric oxide system and, in preclinical work, reduces inflammatory signaling and oxidative stress markers throughout the body.[5]
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of 15 amino acids (GEPPPGKPADDAGLV, MW about 1419). Its sequence corresponds to a partial, N-terminal segment of a larger protective protein found in human gastric juice. The intact 15-residue peptide does not occur naturally in the body, but it is thought to mirror part of the stomach's own ability to protect and repair itself.
BPC-157 has been the subject of more than 200 published reports investigating its regenerative properties across multiple body systems. Most of this work comes from a single research group in Croatia and is preclinical (cell and animal studies), so it should be read as promising early science rather than confirmed human evidence. Its unusual stability in gastric acid sets it apart from most peptides and is the basis for both oral and injectable use.
BPC-157 appears to work through several interconnected pathways. In animal wound models it promotes angiogenesis (new blood vessel formation) and increases VEGF expression, which helps deliver oxygen and nutrients to injured tissue.
At the molecular level, studies show BPC-157 activates the FAK-paxillin signaling cascade, which drives the cell migration and survival that underpin tissue repair. It also engages the nitric oxide (NO) system by influencing endothelial NO-synthase (eNOS/Nos3) expression, supporting endothelial protection and vascular integrity.
BPC-157 has also been reported to trigger early growth response gene-1 (Egr-1) and its co-repressor NAB2, setting off a coordinated cascade of cytokine and growth factor production that orchestrates the healing response. These mechanisms are drawn primarily from rodent and in-vitro experiments.
The body's own repair peptide
In preclinical studies BPC-157 engages several regenerative pathways at once, from FAK-paxillin signaling for cell repair to NO-system modulation for vascular protection, producing a coordinated healing response across tissues.
BPC-157 promoted granulation tissue formation, angiogenesis, and collagen production in skin wounds, colon anastomoses, and sponge implant models. Effects were seen across several routes of administration, including intragastric.
Seiwerth S, Sikiric P, Grabarevic Z, Zoricic I, et al. · Journal of Physiology Paris, 91(3-5):173-178 (1997) · PubMed
BPC-157 dose-dependently increased FAK and paxillin phosphorylation, accelerating tendon fibroblast outgrowth, survival, and migration. Conducted by an independent group at Chang Gung University in Taiwan.
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH · Journal of Applied Physiology, 110(3):774-780 (2011) · PubMed
An independent review from Loughborough University found consistently positive soft-tissue healing effects for tendon, ligament, and muscle, with few reported adverse reactions, while noting that the evidence base is almost entirely preclinical.
Gwyer D, Wragg NM, Wilson SL · Cell and Tissue Research, 377(2):153-159 (2019) · PubMed
A formal toxicology package found BPC-157 well tolerated, with no genetic toxicity or embryo-fetal toxicity and only mild local irritation. This independent dataset reinforces the favorable safety signal seen across the literature.
Xu C, Sun L, Ren F, Huang P, et al. · Regulatory Toxicology and Pharmacology, 114:104665 (2020) · PubMed
The peptide's developers report that BPC-157 was safe and well-tolerated in early-phase trials for inflammatory bowel disease. These trials are referenced in the literature rather than published as standalone reports with full efficacy data, so they remain the most advanced but still limited human evidence.
Sikiric P, Seiwerth S, Brcic L, Blagaic AB, et al. · Inflammopharmacology, 14(5-6):214-221 (2006) · PubMed
start low, go slow
Subcutaneous Injection
Oral
Subcutaneous Injection: Most common route for musculoskeletal injuries. Often injected near the site of injury when feasible.
Oral: Often preferred for gut-related conditions. BPC-157 is unusually stable in gastric acid, remaining active for more than 24 hours.
Dosing should always be determined by a licensed provider based on your specific condition, body weight, and treatment goals.
Typical protocols involve 4–8 weeks on followed by 2–4 weeks off. Many patients report noticeable improvements within the first 1–2 weeks, though these are individual reports rather than trial outcomes.
BPC-157 is commonly combined with Thymosin Beta-4 (TB-500) for healing protocols, though this combination has not been formally studied in humans.
In preclinical toxicology, no lethal dose (LD1) was reached even at doses far above the therapeutic range, and an independent regulatory toxicology package reported no genetic or embryo-fetal toxicity, suggesting a wide safety margin in animals.
In the early human inflammatory bowel disease trials referenced by its developers, BPC-157 was reported as well-tolerated with no reported toxicity.
Long-term human safety data are limited, and most evidence comes from animal studies by a single research group. BPC-157 is not FDA-approved as a drug for any indication.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| BPC-157 | Recovery & Healing | Injection, Oral | 4–8 weeks | Unusually stable in gastric acid; broad multi-system healing signal, though evidence is largely preclinical |
| GHK-Cu | Anti-Aging & Skin Regeneration | Topical, Injection | 8-12 weeks | A naturally occurring copper-carrier peptide that rebuilds the skin matrix and, per gene-expression analysis, shifts expression of about a third of human genes toward repair |
| CJC-1295 | Anti-Aging & Recovery | Subcutaneous injection (weekly with DAC, daily without) | 8-12 weeks | The only GHRH analog with a covalent albumin-binding Drug Affinity Complex, extending its half-life to 6-8 days for once-weekly dosing |
| Thymosin Beta-4 | Recovery & Healing | Injection | 6–12 weeks | The repair peptide best known for reactivating dormant cardiac progenitor cells in animal hearts, with early human trial data in dry eye |
| KPV | Anti-Inflammatory & Wound Healing | Injection, Oral, Topical, Nasal | 4 to 8 weeks | One of the smallest anti-inflammatory peptides, blocking NF-kB nuclear import via PepT1-mediated uptake without melanocortin receptor binding, cAMP elevation, or pigmentation |
The FDA placed this substance in Category 2 of the 503A bulk drug substances evaluation, flagging significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare it and many physicians hesitate to prescribe it.
In April 2026, HHS Secretary Robert F. Kennedy Jr. announced that nominators withdrew 12 peptides from Category 2 of the FDA's 503A bulk drug substances evaluation, including this one. The FDA referred them to its Pharmacy Compounding Advisory Committee (PCAC) for re-evaluation at meetings beginning July 2026. If PCAC recommends Category 1 status and the FDA agrees, licensed 503A pharmacies could compound it under FDA enforcement discretion again. The outcome is not final.
Listed in 503A Category 2 since September 2023. FDA identified immunogenicity risks for injectable routes and complexities with peptide-related impurities. The nominator withdrew the nomination in September 2024, but FDA is continuing evaluation. Not eligible for compounding under the interim policy.
Placed in 503A Category 2 with significant safety risks identified for compounding
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Looking into BPC-157? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA tripeptide-copper complex that supports skin regeneration and wound healing.
Naturally occurring in plasma; levels decline with age. Widely used in topical and compounded formulations.
A stabilized GHRH analog designed to extend the half-life of natural growth hormone pulses.
Widely compounded before 2023; currently flagged by FDA for aggregation and immunogenicity concerns.
A 43-residue peptide involved in actin dynamics, angiogenesis, and tissue repair.
Marketed as TB-500 in fragment form; angiogenesis mechanism raised tumor-growth concerns during FDA review.
“Specializing in Aesthetics and Wellness ”
“Advanced peptide therapies and personalized luxury care for optimal health, vitality, and longevity.”
Vetted providers offering BPC-157.